PLoS ONE (Jan 2012)

Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile.

  • José R Santos,
  • José Moltó,
  • Josep M Llibre,
  • Eugenia Negredo,
  • Isabel Bravo,
  • Arelly Ornelas,
  • Bonaventura Clotet,
  • Roger Paredes

DOI
https://doi.org/10.1371/journal.pone.0037442
Journal volume & issue
Vol. 7, no. 5
p. e37442

Abstract

Read online

BackgroundSimplification of antiretroviral treatment (ART) with darunavir/ritonavir (DRV/r) monotherapy has achieved sustained suppression of plasma viral load (pVL) in clinical trials; however, its effectiveness and safety profile has not been evaluated in routine clinical practice.Methodology/principal findingsWe performed a retrospective cohort analysis of HIV-1-infected patients who initiated DRV/r monotherapy once daily with a pVL 50 copies/mL) at week 48, and time to VF. Other causes of treatment discontinuation and changes in lipid profile were evaluated up to week 48. Ninety-two patients were followed for a median (IQR) of 73 (57-92) weeks. The median baseline and nadir CD4+ T-cell counts were 604 (433-837) and 238 (150-376) cells/mm3, respectively. Patients had previously received a median of 5 (3-9) ART lines and maintained a pVLConclusions/significanceTreatment simplification with DRV/r monotherapy seems safe and effective in routine clinical practice. Further research is needed to elucidate the effect of DRV/r monotherapy on cholesterol levels.